ST. VINCENT HOSPITAL
- Type
- Teaching hospital
- Where
- SHEBOYGAN, WI
- Medicare CCN
- 520075
- Received
- $343,659 in 20 records, 2025 ($2,158 general, $341,501 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 3 | $2,158 |
| 2025 | Research payment | 17 | $341,501 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 6 | $245,320 | 2025 |
| E.R. Squibb & Sons, L.L.C. | 1 | $53,311 | 2025 |
| PFIZER INC. | 2 | $20,000 | 2025 |
| National Marrow Donor Program | 1 | $7,000 | 2025 |
| Merck Sharp & Dohme LLC | 3 | $6,319 | 2025 |
| JAZZ PHARMACEUTICALS INC. | 2 | $5,000 | 2025 |
| ABBVIE INC. | 2 | $4,550 | 2025 |
| Intuitive Surgical, Inc. | 1 | $2,000 | 2025 |
| Becton, Dickinson and Company | 1 | $100 | 2025 |
| B. Braun Interventional Systems Inc. | 1 | $58 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 17 | $341,501 |
| Education | 1 | $2,000 |
| Long term medical supply or device loan | 1 | $100 |
| Debt forgiveness | 1 | $58 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $134 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $134 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro | 2025 |
| 2025-12-17 | B. Braun Interventional Systems Inc. | $58 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-03 | Becton, Dickinson and Company | $100 | Long term medical supply or device loan | In-kind items and services | Alaris Device, Catheter Care and Medication Delivery | 2025 | |
| 2025-11-17 | ABBVIE INC. | $1,950 | Research payment | Cash or cash equivalent | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult P | 2025 | |
| 2025-11-14 | Intuitive Surgical, Inc. | $2,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2025 | |
| 2025-10-31 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA | 2025 |
| 2025-10-31 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA | 2025 |
| 2025-09-26 | National Marrow Donor Program | $7,000 | Research payment | Cash or cash equivalent | A Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistimab Alone versus Lenalidomide Alone in Parti | 2025 | |
| 2025-05-07 | ABBVIE INC. | $2,600 | Research payment | Cash or cash equivalent | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult P | 2025 | |
| 2025-04-16 | Merck Sharp & Dohme LLC | $6,050 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous | 2025 |
| 2025-04-07 | E.R. Squibb & Sons, L.L.C. | $53,311 | Research payment | Cash or cash equivalent | IDHIFA Drug, Hematology | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myel | 2025 |
| 2025-03-05 | JAZZ PHARMACEUTICALS INC. | $3,000 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) | 2025 |
| 2025-03-05 | JAZZ PHARMACEUTICALS INC. | $2,000 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) | 2025 |
| 2025-01-31 | Eli Lilly and Company | $734 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 | |
| 2025-01-23 | Eli Lilly and Company | $251 | Research payment | In-kind items and services | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2025 | |
| 2025-01-21 | Eli Lilly and Company | $129,026 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 | |
| 2025-01-20 | Eli Lilly and Company | $873 | Research payment | In-kind items and services | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 | |
| 2025-01-07 | Eli Lilly and Company | $79,943 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2025 | |
| 2025-01-07 | Eli Lilly and Company | $34,492 | Research payment | Cash or cash equivalent | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Sheboygan, WI, county Sheboygan County, WI, state Wisconsin; placed by its city name.
| Measure | Place (city or town) Sheboygan, WI | County Sheboygan County, WI | State Wisconsin |
|---|---|---|---|
| Population B01003 | 49,645 | 117,991 | 5,914,872 |
| Population, 2020 census P1 | 49,929 | 118,034 | 5,893,718 |
| Median age B01002 | 36.8 | 41.7 | 40.2 |
| Under 18 B01001 | 24.3% | 21.5% | 21.4% |
| 65 and over B01001 | 15.4% | 19.6% | 18.5% |
| Households B11001 | 21,361 | 49,725 | 2,479,480 |
| Foreign born B05002 | 9.6% | 5.8% | 5.2% |
| Median household income B19013 | $62,927 | $73,094 | $77,485 |
| Median family income B19113 | $78,243 | $95,050 | $100,141 |
| Per capita income B19301 | $33,174 | $40,078 | $43,373 |
| Poverty rate B17001 | 12.3% | 8.5% | 10.6% |
| Unemployment rate B23025 | 2.7% | 2.7% | 3.2% |
| Civilian labor force B23025 | 26,297 | 62,060 | 3,132,770 |
| Mean commute (minutes) B08013 | 17.2 | 18.2 | 22.2 |
| Bachelor's degree or higher B15003 | 23.4% | 27.5% | 33.4% |
| Housing units B25001 | 22,759 | 53,067 | 2,778,572 |
| Owner-occupied B25003 | 60.9% | 71.5% | 67.8% |
| Renters B25003 | 39.1% | 28.5% | 32.2% |
| Median home value B25077 | $174,200 | $232,700 | $266,500 |
| Median gross rent B25064 | $924 | $934 | $1,087 |
| White, not Hispanic B03002 | 68.4% | 80.8% | 78.6% |
| Black B03002 | 2.9% | 2.1% | 5.9% |
| Hispanic or Latino B03002 | 12.9% | 7.8% | 8.0% |
| Asian B03002 | 11.1% | 5.8% | 2.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.5% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Sheboygan, WI.
Comments